Posted by Michael Wonder on 21 Dec 2016
Decision to list oral betaine for rare disorder
21 December 2016 - PHARMAC is pleased to announce the approval of an agreement with Emerge Health to list oral betaine powder (Cystadane).
This is the tenth and final product to be listed following a Request for Proposals PHARMAC ran in 2014, related to the supply of medicines for rare disorders. This was the subject of a consultation letter dated 16 November 2016.
The decision means that betaine (Cystadane) will be funded in the community under Special Authority criteria, and in DHB hospitals subject to restrictions, for the treatment of homocystinuria.
Listing in the Pharmaceutical Schedule will occur after any Medsafe approval of the medicine. The decision is as consulted on, with the exception of some changes to the Special Authority criteria. Detail of the decision is set out on the following pages.
